Advertisement

Topics

Takeda to sell dry eye drug to Novartis for up to $5.3bn

06:29 EDT 9 May 2019 | pharmaphorum

Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts following its merger with Shire earlier this year. In order t...

Original Article: Takeda to sell dry eye drug to Novartis for up to $5.3bn

NEXT ARTICLE

More From BioPortfolio on "Takeda to sell dry eye drug to Novartis for up to $5.3bn"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...